( July 30, 2026, 14:21 GMT | Official Statement) -- MLex Summary: Eli Lilly's proposed $3.8 billion acquisition of AtaiBeckley will require antitrust approval in Australia and Germany, according to a securities filing. "In addition to the requirements under the HSR Act, the closing of the merger is conditioned on the receipt, expiration or termination of the antitrust notices, approvals, clearances and waiting periods required under the antitrust laws of Australia and Germany, as well as the antitrust laws of specified other jurisdictions, if applicable (the 'Springing Jurisdictions')," the securities filing said. The companies expect the deal to close in the third quarter of 2026.Excerpt:...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.